| Project/Area Number |
20790568
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Tottori University |
|---|
Principal Investigator |
MATSUMOTO Shingo Tottori University, 医学部附属病院, 助教 (10392341)
|
|---|
| Research Collaborator |
NAKAMOTMO Masaki 鳥取大学, 医学部, 助教
HASHIMOTO Kiyoshi 鳥取大学, 医学部, 助教
TAKEDA Kennichi 鳥取大学, 医学部, 大学院生
NAKAZAKI Hirofumi 鳥取大学, 医学部, 大学院生
|
|---|
| Project Period (FY) |
2008 – 2009
|
| Project Status |
Completed (Fiscal Year 2009)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2009: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2008: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | 肺癌 / LKB1 / 抗癌剤感受性 / mTOR阻害剤 / PTEN / 非小細胞肺癌 |
|---|
| Research Abstract |
Individualized drug therapies based on characteristics of cancer cell are needed to improve prognoses of lung cancer patients. It has been reported that targeted agents against activated molecules responsible for cancer developments and progressions were effective in several malignant tumors including lung cancers. Mutations of the LKB1 gene and the PTEN gene that activate mTOR signaling, resulting in cell proliferations, are frequently occurred in lung cancers. In the present study, we revealed that lung cancer cells with LKB1 or PTEN mutations were more sensitive to a mTOR inhibitor than those without the mutations. Thus, it is indicated that the new individualized drug therapy based on the gene mutations might be clinically useful for lung cancers.
|
